ProfileGDS5678 / 1443883_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 49% 55% 47% 58% 55% 58% 50% 53% 51% 53% 53% 53% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2829869
GSM967853U87-EV human glioblastoma xenograft - Control 23.1482349
GSM967854U87-EV human glioblastoma xenograft - Control 33.3570255
GSM967855U87-EV human glioblastoma xenograft - Control 43.0489347
GSM967856U87-EV human glioblastoma xenograft - Control 53.4459558
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4658255
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5930358
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1927450
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2705853
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2059351
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.304953
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2740153
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3116453
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3105953